Breast cancer heterogeneity represents a major hurdle to improve patient survival. Notwithstanding its potential curability due to the availability of treatment modalities that are effective in the presence of favourable clinical or patho-biologic features, there is still a great deal of controversy in ...
Described herein is the use of Agouti Signaling Protein (ASIP), in addition to certain other melanocortin signaling network (MSN) genes, as prognostic and predictive biomarkers for the progression of breast cancer. In particular, the novel biomarkers can be used to determine if a female breast ...
Kaiso, a transcriptional regulator with bimodal DNA-binding specificity, is over-expressed in breast cancer cells, and its nuclear localization is correlated with malignant and lymph node metastasis. Depleted expression of Kaiso in those cells results in a significant decrease in basal and EGF-induced...
Single-cell combined with bulk-RNA data reveal a pattern related to angiogenesis in breast cancer patients: Individualized medicine [ARGs]) have been identified as diagnostic biomarkers of breast cancer in a few studies, the mixed effects of ARGs have not been thoroughly investigated... W Zhang...
Breast cancer is a heterogeneous disease. For the past decades, new technical tools have been developed for biomarkers at the DNA, RNA, and protein levels to better understand the biology of breast cancer. This progress is essential to classify the disease into clinically relevant subtypes, which...
以乳腺癌为例,在Search Tumor Type栏输入或下拉选择Breast cancer,回车可得到检索结果,共有21个基因及对应的37种药物注释信息,其中Level1~4包含的基因分别为6、2、4和11个,LevelR1~2包含的基因分别为0和2个。页面下拉可以看到不同级别对应的基因名称、突变类型和相关药物。
The invention includes the identification and use of biomarkers that are present in different amount or differentially expressed in breast cancer versus normal controls.doi:US20110207156 A1Mark W. DuncanLindsay WeitzelAnthony EliasTimothy ByersUS
This consensus statement revises and updates the recommendations for biomarkers use in the diagnosis and treatment of breast cancer, and is a joint initiative of the Spanish Society of Medical Oncology and the Spanish Society of Pathology. This expert group recommends determining in all cases of bre...
Breast cancer is the most common malignancy among women globally. Development of a reliable plasma biomarker panel might serve as a non-invasive and cost-effective means for population-based screening of the disease. Transcriptomic profiling of breast tu
Breast cancer is a major cause of cancer mortality worldwide. Fascin-1 (FSCN1) is an actin-binding protein found in mammalian cells, including endothelial, neuronal and mesenchymal cells. FSCN1 overexpression has been indicated in breast cancer patients. However, scant information is available regar...